What are the key sales KPIs for the Pharmacy Benefit Manager (PBM) industry in 2027?

What it is and why it matters

A Pharmacy Benefit Manager sits in the middle of a three-sided market: plan sponsors (employers, health plans, and Medicare Part D carriers) on one side, drug manufacturers on another, and dispensing pharmacies on the third. Every prescription that moves through that triangle throws off revenue in four separate pools, and understanding which pool a given metric protects is the first thing anyone new to the industry has to learn. The first pool is the PMPM admin fee the plan sponsor pays for administering the benefit. The second is rebate retention — the cut of manufacturer rebates the PBM keeps rather than passing back to the plan sponsor. The third is spread pricing, the gap between what the PBM reimburses the pharmacy and what it bills the plan. The fourth is dispensing margin earned directly by PBM-owned mail-order and specialty pharmacies. Historically, pools two and three dwarfed the admin fee — a PBM could quote a plan sponsor a near-zero PMPM fee because the real money was made invisibly, in rebates and spread. That arrangement is being dismantled in real time and it is why every KPI on this page has to be read against the backdrop of a mandated pricing overhaul.

Three companies still dominate the industry: CVS Caremark, Express Scripts (Cigna Evernorth), and OptumRx (UnitedHealth Group), together adjudicating roughly 80% of U.S. 30-day-adjusted prescription claims. CVS Caremark processed approximately 1.9 billion adjusted claims in 2025 (about 31% share, down slightly year over year), Express Scripts pulled ahead in volume after absorbing the Centene book, and OptumRx holds roughly 20% share after losing the CalPERS contract to Caremark for the 2026 plan year. Scale matters here because claim volume is the base unit every other metric is expressed against — a rebate-retention percentage or a formulary-adherence rate means very little without the claim count it is applied to.

The reason specialty pharmacy dominates every current strategy conversation is margin concentration: specialty scripts are under 2% of total prescription volume but drove roughly $293.4 billion in dispensing revenue in 2025, up 9.6% year over year, and more than half of total plan drug spend. The three largest specialty pharmacies in the country are all owned by the Big-3 PBMs and together capture close to two-thirds of pharmacy-dispensed specialty revenue. That concentration is precisely why regulators intervened: the Consolidated Appropriations Act of 2026 requires ERISA group health plans to receive 100% of manufacturer rebates, and the FTC's February 2026 settlement with Express Scripts forces a shift to cost-plus reimbursement and eliminates spread pricing on that book. CVS Caremark's "TrueCost" and OptumRx's "Cost Clarity" are the industry's answer, with full rollout targeted by 2028. Every metric on a PBM scorecard now has to be interpreted through that lens — is it a legacy metric measuring a business model that is being phased out, or a forward metric measuring the cost-plus replacement.

The step-by-step process

Building a working KPI program inside a PBM is a sequencing problem, not a dashboard problem — you cannot report Rebate Retention accurately until claim volume reconciles, and you cannot forecast PMPM pricing until you know the client's specialty mix. The practical build order looks like this:

Step 1 — Reconcile claim volume. Pull 30-day-adjusted claim counts from the adjudication platform (RxClaim or equivalent), from finance's billed-claims ledger, and from the rebate aggregator's own claim feed. These three sources disagree on day one in virtually every PBM implementation, usually because of timing differences in how 90-day mail fills are adjusted to 30-day equivalents. Resolve the reconciliation gap before trusting any downstream number.

Step 2 — Baseline the formulary metrics. Once claim volume is trustworthy, calculate Generic Dispensing Rate and Formulary Adherence per client. These two metrics feed directly into the rebate calculation, so they have to be locked before rebate figures are published.

Step 3 — Segment specialty and mail. Break out Specialty Pharmacy Mix % and Mail-Order Penetration % by therapy category and by channel (owned vs network). This is where the highest-margin and most strategically sensitive numbers live, and it is usually the step that surfaces steerage patterns worth flagging to legal.

Step 4 — Publish the rebate bridge. Show, client by client, the legacy rebate-retention number next to the new 100%-pass-through-plus-PMPM-fee number. This bridge is what plan sponsors and their consultants (Aon, Mercer, WTW) are now demanding in every RFP.

Step 5 — Roll up to retention and P&L. Client Retention % and 340B Contract-Pharmacy Revenue close the loop, feeding the quarterly business review and the renewal pipeline.

Costs, timelines, and typical ranges

Every KPI on this page has a benchmark range, and the ranges matter more than the point estimates because they tell you whether a client relationship is healthy or leaking value. Generic Dispensing Rate: industry average sits in the high 80s, with best-in-class PBMs running 90% or higher; a single percentage point of GDR improvement is roughly a 5% reduction in a plan's gross drug spend, which is why GDR is contractually guaranteed on most large-employer deals. Specialty Pharmacy Mix: under 2% of scripts, 50%+ of spend, with the category growing at high-single-digit rates annually — a PBM whose specialty mix is materially below that band is either under-capturing specialty steerage or serving a client population skewed toward maintenance therapy. Client Retention: best-in-class PBMs hold 95%+ annual retention on employer and health-plan books, with the industry average in the 90–93% range; anything below 90% on a book of meaningful size should trigger an immediate root-cause review, because a single large non-renewal (Anthem leaving Express Scripts in 2019, CalPERS leaving OptumRx in 2026) can move billions of scripts in one cycle.

PMPM Admin Fee is the metric undergoing the fastest structural change. Under the legacy rebate-subsidized model, PMPM fees ran $0.50–$2.00 per member per month because the PBM's real profit came from rebate retention and spread, not the visible fee line. Under the cost-plus, 100%-pass-through model mandated by the 2026 CAA and the FTC settlement, the replacement fee is migrating to a $5–$15 PMPM range — a five-to-ten-fold increase in the visible line item, even though total plan cost is intended to be roughly neutral or lower once hidden spread is removed. This repricing is happening on a multi-year timeline: the FTC settlement targets full cost-plus implementation by 2028, so 2027 is a transition year in which PBMs are running dual books — legacy rebate-retention contracts in run-off alongside new pass-through-plus-PMPM contracts in run-on. Formulary Adherence above 85% is considered healthy; below 75% signals value leakage through prior-authorization failures and non-preferred fills. Mail-Order Penetration targets of 25–35% on maintenance categories are standard because mail margins run 200–400 basis points above retail-network spread. 340B Contract-Pharmacy Revenue is the most volatile line on the list — manufacturer restrictions imposed by Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim, among others, have been cutting covered-entity revenue at safety-net providers since 2023, and that pressure is expected to continue through 2027.

Where teams get it wrong

The single most common failure is rebate-retention denial: building 2027 and 2028 financial models on legacy rebate-retention assumptions when the Consolidated Appropriations Act and the FTC consent order explicitly prohibit that revenue structure going forward. Teams that don't rebuild their P&L around the pass-through-plus-PMPM model discover the gap only at the annual true-up, by which point it is a 200–400 basis-point EBITDA miss that cannot be recovered mid-contract.

The second failure is over-aggressive specialty steerage. Because specialty pharmacy is the highest-margin pool in the entire business, there is constant internal pressure to route more specialty scripts to owned pharmacy. Pushed too hard, this invites state attorney general scrutiny and ERISA fiduciary-breach litigation from plan sponsors who argue the steerage prioritized PBM margin over member cost and choice. The fix is a documented, clinically justified steerage policy reviewed by compliance, not a sales target.

The third failure is client-concentration blindness. When a single health-plan or PBM-aggregator relationship represents 15% or more of total book (as Centene did for Express Scripts, or Anthem did for Express Scripts in an earlier cycle), the loss of that one contract at renewal moves billions of scripts and can single-handedly wreck a quarter. Teams that don't actively diversify book composition, or that don't build contingency volume plans for their top three clients, are exposed to a cliff they can see coming years in advance and often fail to plan for anyway.

The fourth failure is PMPM underpricing. As PBMs migrate clients from rebate-subsidized fees to cost-plus PMPM fees, there is commercial pressure to underprice the new fee to win or retain the account. If the fee is set below what is actually required to recover the lost rebate-retention margin, the gap surfaces only at the next contractual true-up — usually a year later, after the damage is already locked into a multi-year agreement.

Decision framework: when to choose what

Not every client or every metric warrants the same reporting cadence, and matching cadence to metric type is itself a decision PBM operating teams have to make deliberately. Fast-moving operational metrics — claims processed, network rejections, prior-authorization turnaround, specialty fill rates — need daily visibility because a spike in rejections or a stall in prior-auth turnaround is a member-experience problem that compounds by the hour. Metrics that reflect formulary and channel behavior — GDR by client, formulary adherence, mail-order penetration, service-level agreements — move slowly enough that a weekly operating review is the right cadence; checking them daily produces noise, not signal. Financial and margin metrics — PMPM actual versus target, specialty margin by therapy area, rebate accrual versus pass-through actuals, client-level P&L — belong in a monthly business review, because they depend on billing cycles that don't resolve faster than that. Strategic metrics — retention pipeline, regulatory exposure, 340B contract pipeline, full P&L by line of business — belong in the quarterly board and earnings cycle, where the decision being made is about capital allocation and contract strategy rather than day-to-day operations.

The same logic applies to choosing between rebate-retention and cost-plus pricing on a given contract: if a client's specialty mix is high and formulary adherence is strong, the rebate pool is large enough that a pass-through-plus-modest-PMPM structure is usually competitive; if specialty mix is low and the client is price-sensitive on the visible fee line, a straightforward cost-plus PMPM in the $8–$12 range, run transparently, tends to win RFPs against legacy-model competitors in 2027.

Related questions

How is a 30-day adjusted script calculated?

It converts every fill to a common 30-day-supply unit, so a 90-day mail-order fill counts as three scripts. This standardizes volume comparisons across retail, mail, and specialty channels for both revenue and rebate calculations.

What triggered the shift away from rebate retention?

The Consolidated Appropriations Act of 2026 mandated 100% rebate pass-through to ERISA group plans, and the FTC's February 2026 settlement with Express Scripts separately forced cost-plus reimbursement and ended spread pricing on that PBM's book.

Why do PBMs want higher mail-order penetration?

Mail-order dispensing carries margins roughly 200–400 basis points above retail-network spread on maintenance medications, so PBMs target 25–35% mail penetration on those categories to improve blended profitability.

What is 340B contract-pharmacy revenue?

It is fee revenue earned administering discounted drug programs for covered entities like safety-net hospitals and community health centers. It's currently the fastest-growing PBM-adjacent revenue line but also the most exposed to manufacturer-imposed restrictions.

FAQ

What is a 30-day adjusted script and why does it matter? A 30-day adjusted script converts all prescription fills to a common 30-day supply unit, so a 90-day mail-order fill counts as three scripts. This standardizes volume across channels and is the primary driver of per-claim revenue in both rebate and cost-plus models.

How does rebate retention differ from pass-through in 2027? Rebate retention is the share of manufacturer rebates the PBM keeps as profit; pass-through means 100% of rebates go to the plan sponsor. Under the 2026 reforms, most large PBMs are shifting profit from hidden rebate spreads to transparent PMPM admin fees instead.

What is a healthy generic dispensing rate for a PBM? Industry benchmarks typically run in the high 80s to low 90s percent. A higher GDR lowers plan drug costs and reduces exposure to brand-price inflation, making it one of the most closely contractually monitored metrics in the industry.

Why is specialty pharmacy mix such a critical metric? Specialty drugs are under 2% of prescription volume but over half of total plan drug spend, and dispensing revenue is heavily concentrated among the three largest, PBM-owned specialty pharmacies. Specialty mix is the single biggest lever on gross margin in the entire model.

What drives client retention in the PBM industry? Annual retention among employer and health-plan clients typically runs 90–95%. The main drivers are transparent pricing, formulary flexibility, demonstrated net cost savings versus competitors, and service-level performance on claims and prior authorization.

How are PMPM admin fees changing under cost-plus models? Legacy PMPM fees ran $0.50–$2.00, subsidized by rebate retention. Under 2027 cost-plus structures, fees are migrating to roughly $5–$15 per member per month, reflecting the true administrative and clinical cost of running the benefit transparently.

Sources

• https://www.drugchannels.net
• https://www.pbmi.com
• https://www.ftc.gov
• https://www.cvshealth.com/investors
• https://www.cigna.com/investors
• https://www.unitedhealthgroup.com/investors
• https://www.kff.org
• https://www.ncpa.org
• https://www.ajmc.com
• https://www.frierlevitt.com

Related on PULSE

• [Top 10 Pharmacy Retail Revenue KPIs](/knowledge/ik0667)
• [What are the key sales KPIs for the Retail Pharmacy Chain industry in 2027?](/knowledge/ik0334)
• [What are the key sales KPIs for the Veterinary Compounding Pharmacy Services industry in 2027?](/knowledge/ik0268)
• [What are the key sales KPIs for the Specialty Pharmacy Distribution industry in 2027?](/knowledge/ik0130)
• [What are the key sales KPIs for the Commercial Specialty Pharmacy industry in 2027?](/knowledge/ik0108)